According to a study published in the Journal of Gastroenterology, canagliflozin may improve liver function, reduce glycosylated hemoglobin (HbA1c) and body weight, and be well tolerated in type 2 diabetes patients with impaired liver function. This was a post-hoc analysis and was divided into 2 studies, 1 and 2. The first one was the pooled analysis of 12- and 24-week placebo-controlled, monotherapy study while the second one was 52-week monotherapy/combination therapy study. The findings showed that the mean alanine aminotransferase (ALT) change at 12 weeks was -10.3 ± 11.7 and -3.2 ± 17.6 U/L in the canagliflozin vs. placebo group in the high ALT sub-group. However, no marked difference was seen in the low ALT sub-group (study 1). In both ALT sub-groups, HbA1c and body weight were reduced remarkably in the canagliflozin vs. placebo group. In study 2, the mean change in ALT at 52 weeks was -16.0 ± 18.8 U/L in the high ALT sub-group.